CA2524551C - Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer - Google Patents

Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2524551C
CA2524551C CA2524551A CA2524551A CA2524551C CA 2524551 C CA2524551 C CA 2524551C CA 2524551 A CA2524551 A CA 2524551A CA 2524551 A CA2524551 A CA 2524551A CA 2524551 C CA2524551 C CA 2524551C
Authority
CA
Canada
Prior art keywords
selenium
subject
disease
sel
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2524551A
Other languages
English (en)
Other versions
CA2524551A1 (fr
Inventor
Thomas Pearse Lyons
Ronan Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Priority to CA2524551A priority Critical patent/CA2524551C/fr
Publication of CA2524551A1 publication Critical patent/CA2524551A1/fr
Application granted granted Critical
Publication of CA2524551C publication Critical patent/CA2524551C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions et des procédés qui permettent de modifier la fonction cellulaire. En particulier, la présente invention concerne des compositions qui comprennent du sélénium (par exemple, Sel-Plex) ainsi que des procédés pour les utiliser (par exemple, comme traitement thérapeutique et/ou prophylactique de maladies neurodégénératives). En outre, la présente invention démontre que des formes particulières de sélénium (par exemple, Sel-Plex) possèdent la capacité de modifier lexpression de gènes associés à une maladie et/ou au vieillissement alors que dautres formes de sélénium (par exemple, sélénométhionine) ne possèdent pas cette capacité.
CA2524551A 2005-10-14 2005-10-25 Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer Expired - Lifetime CA2524551C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2524551A CA2524551C (fr) 2005-10-14 2005-10-25 Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USUNKNOWN 2002-03-13
CA2524551A CA2524551C (fr) 2005-10-14 2005-10-25 Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
CA2524551A1 CA2524551A1 (fr) 2007-04-14
CA2524551C true CA2524551C (fr) 2014-12-16

Family

ID=37913463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2524551A Expired - Lifetime CA2524551C (fr) 2005-10-14 2005-10-25 Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer

Country Status (1)

Country Link
CA (1) CA2524551C (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665135C2 (ru) * 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用

Also Published As

Publication number Publication date
CA2524551A1 (fr) 2007-04-14

Similar Documents

Publication Publication Date Title
CA2650309C (fr) Compositions contenant du selenium et utilisation de celles-ci
AU2005227420B2 (en) Method and compositions for altering cell function
US20110038889A1 (en) Methods and compositions for altering cell function
Benedetto et al. Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson’s disease
Ludolph et al. The role of excitotoxicity in ALS–what is the evidence?
US8865763B2 (en) Methods and compositions for altering cell function
Crouch et al. Mitochondria in aging and Alzheimer's disease
US8871715B2 (en) Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20070155687A1 (en) Methods and compositions for altering cell function
US20100247679A1 (en) Methods and compositions for altering cell function
AU2013205053B2 (en) Method and compositions for altering cell function
CA2524551C (fr) Utilisation de levures de selenium dans le traitement de la maladie d'alzheimer
Mani et al. Pharmacological Management of Amyotrophic Lateral Sclerosis
WO2003094934A1 (fr) Médicament pour prévenir et traiter l'amyloïdose
KR20240017731A (ko) Pdh 억제제의 신경 퇴행성 질환 치료 용도
Liu et al. Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications. Front. Neurosci. 12: 632. doi: 10.3389/fnins. 2018.00632 Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications Jun-Lin Liu¹†
HK1113654A (en) Methods and compositions for altering cell function
Hariprasad Pharmacological Evaluation of Novel Drugs in Rat Models of Peripheral Neuropathy

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241126

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241204